Itolizumab

Itolizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	CD6
Clinical data
Trade names	Alzumab
ATC code	none;
Legal status
Legal status	Approved in India;
Identifiers
CAS Number	1116433-11-4 ;
ChemSpider	none;
UNII	XQQ2RHV14N;
KEGG	D12426;
	(what is this?) (verify)

Itolizumab (INN, trade name Alzumab) is a 'first in class' humanized IgG1 monoclonal antibody developed by Biocon^[1] and the Center of Molecular Immunology (CIM), Havana.^[2]

^ Jayaramun K (December 2013). "Biocon's first-in-class anti-CD6 mAb reaches the market". Nat. Biotechnol. Vol. 31, no. 12. United Kingdom. pp. 1062–3.
^ "India prepares to test Itolizumab, the drug credited for lowering Covid mortality in Cuba". May 30, 2020.

[jayaraman2013-1] Jayaramun K (December 2013). "Biocon's first-in-class anti-CD6 mAb reaches the market". Nat. Biotechnol. Vol. 31, no. 12. United Kingdom. pp. 1062–3.

[2] "India prepares to test Itolizumab, the drug credited for lowering Covid mortality in Cuba". May 30, 2020.

[1]

[2]